RECKITT BENCKIS/S (OTCMKTS:RBGLY) – Equities research analysts at Jefferies Financial Group decreased their FY2020 earnings per share (EPS) estimates for RECKITT BENCKIS/S in a note issued to investors on Friday, November 15th. Jefferies Financial Group analyst M. Deboo now anticipates that the company will post earnings of $0.83 per share for the year, down from their previous forecast of $0.86. Jefferies Financial Group also issued estimates for RECKITT BENCKIS/S’s FY2021 earnings at $0.84 EPS and FY2022 earnings at $0.86 EPS.
Other analysts also recently issued research reports about the stock. ValuEngine downgraded shares of RECKITT BENCKIS/S from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. Berenberg Bank started coverage on shares of RECKITT BENCKIS/S in a report on Wednesday, October 16th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. RECKITT BENCKIS/S has a consensus rating of “Hold” and an average price target of $19.00.
Shares of OTCMKTS RBGLY opened at $15.67 on Monday. The company has a 50 day simple moving average of $15.50 and a 200-day simple moving average of $15.80. The company has a market capitalization of $53.99 billion, a P/E ratio of 17.41, a P/E/G ratio of 8.80 and a beta of 0.77. RECKITT BENCKIS/S has a 1 year low of $14.42 and a 1 year high of $18.85.
RECKITT BENCKIS/S Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Article: Penny Stocks
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.